Maria Eva Mingot-Castellano, Faustino García-Candel, Jorge Martinez Nieto, José García-Arroba Peinado, Javier de la Rubia Comos, Ines Gomez-Segui, María-Liz Paciello-Coronel, David Valcarcel, Moraima Jiménez, Joan Cid, Miquel Lozano, José-María García-Gala, Sonia Angós-Vazquez, Miriam Vara Pampliega, Luisa Guerra Dominguez, Laura-Francisca Ávila-Idrovo, Ana Oliva Hernandez, Saioa Zalba, Inmaculada Tallón Ruiz, Sandra Ortega Sánchez, Rosa Goterris, Maria Gemma Moreno Jimenez, Lourdes Domínguez-Acosta, María Araiz-Ramírez, Luis M Hernández-Mateo, Elena Flores Ballester, Julio Del Rio-Garma, Cristina Pascual Izquierdo
Caplacizumab prevents the interaction between von Willebrand factor and platelets, and is used to treat immune thrombotic thrombocytopenic purpura (iTTP). Its administration has been associated with a delay in ADAMTS13 activity restoration after plasma exchange (PEX) suspension. We analyzed the outcomes of 113 iTTP episodes, 75 of which were treated with caplacizumab, in 108 patients from the Spanish Registry of Thrombotic Thrombocytopenic Purpura. Caplacizumab shortened the time to platelet count normalization and reduced PEX requirement, exacerbations and relapses...
January 18, 2024: Blood